Eland Oil & Gas Regulatory News (ELA)

13 Apr 2006 12:04

Elan Corporation PLC13 April 2006 ELAN CORPORATION, PLC (the "Company") 13th April 2006 RE: Annual Information Update Annual Information Document for the period from March 31, 2005 up to andincluding April 13, 2006. The Company published its annual financial statementsin respect of the year ended December 31, 2005 on March 31, 2006. This Annual Information Document has been prepared by Elan Corporation, plc inaccordance with the provisions of Part 11 of the Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No. 324 of 2005) and has been submitted to the IrishStock Exchange for filing with the Irish Financial Services Regulatory Authority(the Financial Regulator) in accordance with the Prospectus Rules issued by theFinancial Regulator. The Company is publishing this Annual Information Documentvia an RIS today and making it available on its website www.elan.com.The Companydoes not intend to rely solely on the Financial Regulator to publish the AnnualInformation Document. The information referred to in this document was up to date at the time it waspublished but some information may now be out-of-date. To avoid an unnecessarilylengthy document, information is referred to in this document rather thanincluded in full. 1. Announcements made via RNS, a regulatory information service All of the announcements listed below were published via RNS, a RegulatoryInformation Service and are available for viewing on the Irish Stock Exchangewebsite www.ise.ie. Date Announcement13/04/2006 Holdings in Company11/04/2006 Elan Announces Dates for Upcoming Corporate Events10/04/2006 Brochure of Particulars07/04/2006 New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis03/04/2006 Brochure of Particulars31/03/2006 Elan Announces Filing of 20-F and Annual Report for Year Ended December 31, 200530/03/2006 Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis22/03/2006 Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI(R) for Multiple Sclerosis21/03/2006 Elan Closes Sale of Rights to Prialt In Europe to Eisai13/03/2006 Holdings in Company10/03/2006 Director/PDMR Shareholding09/03/2006 Restoration of Listing09/03/2006 OL Notice - Restoration09/03/2006 FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis07/03/2006 Suspension - Elan Corp Plc07/03/2006 OL Notice - Suspension02/03/2006 TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine; TYSABRI Currently Under Review with U.S. and European Regulatory Authorities01/03/2006 Miscellaneous01/03/2006 Elan Announces the Suspension of Trading of Its Shares Commencing March 7, 2006 For Up to Two Days; Suspension of Trading Due to Two Day FDA Advisory Committee Meeting to Review Tysabri(R)16/02/2006 TYSABRI(R) Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS15/02/2006 Brochure of Particulars10/02/2006 Director/PDMR Shareholding09/02/2006 Director/PDMR Shareholding09/02/2006 Holding in Company09/02/2006 Elan to Sell Rights to Prialt in Europe to Eisai08/02/2006 Director/PDMR Shareholding03/02/2006 Director/PDMR Shareholding31/01/2006 Final Results30/01/2006 Elan Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference25/01/2006 Holding in Company23/01/2006 Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis13/01/2006 Elan Announces Webcast of Fourth Quarter and Full Year 2005 Financial Results10/01/2006 Elan and EntreMed Execute License Agreement for Proprietary NanoCrystal(R) Technology23/12/2005 Elan to Present at Healthcare Conferences in January 200609/12/2005 Director/PDMR Shareholding18/11/2005 Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI(R) in Multiple Sclerosis17/11/2005 RE: Director/PDMR Shareholding10/11/2005 The National MS Society, Biogen Idec, Elan, and MSWorld Recognize MS Leaders of Hope(SM) Award Winners01/11/2005 Director/PDMR Shareholding27/10/2005 3rd Quarter Results17/10/2005 Elan and Biogen Idec Announce TYSABRI(R) Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients; TYSABRI(R) Safety Evaluation Complete; No New Confirmed Cases of PML04/10/2005 Elan Announces Webcast of Third Quarter 2005 Financial Results29/09/2005 Interim Results28/09/2005 Elan Announces Commencement of Exchange Offer for US$1.15 Billion Aggregate Principal Amount of Notes27/09/2005 Biogen Idec and Elan Submit Supplemental Biologics License Application to the FDA for TYSABRI(R) in Multiple Sclerosis22/09/2005 Re: Brochure of Particulars21/09/2005 Elan and Biogen Idec Provide an Update on TYSABRI(R)23/08/2005 Director/PDMR Shareholding19/08/2005 Director/PDMR Shareholding09/08/2005 Biogen Idec and Elan Announce TYSABRI(R) Safety Evaluation Update28/07/2005 Interim Results19/07/2005 Two-Year Sentinel Data Evaluating TYSABRI(R) in Addition to AVONEX(R) Reinforce Efficacy in Multiple Sclerosis14/07/2005 Elan Announces Webcast of Second Quarter 2005 Financial Results07/07/2005 Early Redemption30/06/2005 TYSABRI(R) Phase III Induction Trial in Crohn's Disease Meets Primary Endpoint21/06/2005 Brochure of Particulars14/06/2005 Elan Settles Legal Action with Former CEO08/06/2005 Elan Completes Retirement of over USD 240 Million of 2008 Debt01/06/2005 Elan Retires over $240 Million of 2008 Debt31/05/2005 Elan Announces the Appointment of New Board Directors26/05/2005 Elan Holds Its AGM, All Resolutions Passed17/05/2005 Elan Announces Webcast of Annual General Meeting on May 26, 200503/05/2005 Director Shareholdings28/04/2005 1st Quarter Results26/04/2005 Document Availability15/04/2005 Directors Interests13/04/2005 TYSABRI(R) Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression11/04/2005 Brochure of Particulars11/04/2005 Elan Sets Date of April 28 for First Quarter 2005 Financial Results, and May 26 for the Annual General Meeting07/04/2005 Re: Holding in Company05/04/2005 RE: Holding in Company31/03/2005 Elan and Biogen Idec Announce TYSABRI(R) Update 2. Documents filed with United States Securities and Exchange Commission The following documents have been filed with the US Securities and ExchangeCommission and are available on the Edgar website at http://www.sec.gov/edgar/searchedgar/webusers.htm. Date Filing07/04/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)30/03/2006 20-F Annual and transition report of foreign private issuers (Sections 13 or 15 (d))29/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)22/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)21/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)01/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)01/03/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)28/02/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)15/02/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/02/2006 SC 13G Statement of acquisition of beneficial ownership by individuals13/02/2006 SC 13D/A Amend General statement of acquisition of beneficial ownership09/02/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/01/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)30/01/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)23/01/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)13/01/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/01/2006 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)22/12/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)07/12/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)17/11/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)27/10/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)17/10/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)04/10/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)29/09/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)28/09/2005 424B3 Prospectus (Rule 424(b)(3))28/09/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)26/09/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)20/09/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/09/2005 F-4 Registration of securities, foreign private issuers, business combinations09/09/2005 20-F/A Amend Annual and transition report of foreign private issuers (Sections 13 or 15(d))16/08/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/08/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)28/07/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)18/07/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/07/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)30/06/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/06/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)08/06/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)01/06/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/05/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)26/05/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)17/05/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/05/2005 SC 13D/A Amend General statement of acquisition of beneficial ownership29/04/2005 SC 13D/A Amend General statement of acquisition of beneficial ownership28/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)27/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)13/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/04/2005 SC 13G/A Amend Statement of acquisition of beneficial ownership by individuals11/04/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/04/2005 20-F Annual and transition report of foreign private issuers (Sections 13 or 15 (d))08/04/2005 SC 13G/A Amend Statement of acquisition of beneficial ownership by individuals04/04/2005 4 Statement of changes in beneficial ownership of securities31/03/2005 6-K Report of foreign issuer (Rules 13a-16 and 15d-16) 3. Documents filed with the Registrar of Companies All of the documents listed below were filed with the Registrar of Companies inIreland on the dates indicated. Copies of documents filed with the Registrar ofCompanies are available from the Companies Registration Office at www.cro.ie. Date Filing09/03/2006 B5 Return of Allotments08/03/2006 B5N Allotment of Shares for Cash10/02/2006 B5 Return of Allotments30/01/2006 B5 Return of Allotments20/01/2006 B6 Particulars of a Contract Relating to Shares20/01/2006 B6 Particulars of a Contract Relating to Shares12/01/2006 B5N Allotment of Shares for Cash15/12/2005 B6 Particulars of a Contract Relating to Shares15/12/2005 B6 Particulars of a Contract Relating to Shares28/11/2005 B5N Allotment of Shares for Cash07/11/2005 B5N Allotment of Shares for Cash04/11/2005 B10 Change in Director28/10/2005 B1 Annual Return28/10/2005 Account Details20/10/2005 B6 Particulars of a Contract Relating to Shares12/09/2005 B5N Allotment of Shares for Cash12/09/2005 B6 Particulars of a Contract Relating to Shares22/08/2005 B5N Allotment of Shares for Cash20/07/2005 B6 Particulars of a Contract Relating to Shares18/07/2005 B5N Allotment of Shares for Cash13/07/2005 B5N Allotment of Shares for Cash30/06/2005 B6 Particulars of a Contract Relating to Shares20/06/2005 B5N Allotment of Shares for Cash16/06/2005 B10 Change in Director15/06/2005 B6 Particulars of a Contract Relating to Shares14/06/2005 B6 Particulars of a Contract Relating to Shares14/06/2005 B6 Particulars of a Contract Relating to Shares10/06/2005 G1P Special Resolution10/06/2005 G2E Ordinary Resolution01/06/2005 B5N Allotment of Shares for Cash31/05/2005 B10 Change in Director29/04/2005 B5N Allotment of Shares for Cash15/04/2005 B6 Particulars of a Contract Relating to Shares15/04/2005 B6 Particulars of a Contract Relating to Shares15/04/2005 B6 Particulars of a Contract Relating to Shares01/04/2005 B5N Allotment of Shares for Cash18/03/2005 B5N Allotment of Shares for Cash21/02/2005 B6 Particulars of a Contract Relating to Shares21/02/2005 B6 Particulars of a Contract Relating to Shares14/02/2005 B5N Allotment of Shares for Cash07/02/2005 B2 Change in Registered Office14/01/2005 B6 Particulars of a Contract Relating to Shares14/01/2005 B6 Particulars of a Contract Relating to Shares06/01/2005 B5N Allotment of Shares for Cash 4. Annual and Interim Report 2005 The Company's Annual Report and 20-F for the year ending December 31, 2005 whichwas filed with the Irish Stock Exchange on March 31, 2006, can be found on theCompany's website, as can the Interim Report for the 6 months ended June 30,2005 published on September 29, 2005. A copy of this Annual Information Document and copies of the documents referredto in it can be obtained from the Company Secretary at the Company's RegisteredOffice: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Enquiries: William Daniel Company Secretary +353 1 709 4000 April 13, 2006 This announcement has been issued through the Companies Announcement Service of The Irish Stock Exchange. This information is provided by RNS The company news service from the London Stock Exchange